• Home
  • Search Results
  • In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential.

In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential.

Oncotarget (2014-10-20)
Philipp Raffeiner, Ruth Röck, Andrea Schraffl, Markus Hartl, Jonathan R Hart, Kim D Janda, Peter K Vogt, Eduard Stefan, Klaus Bister

The oncogenic bHLH-LZ transcription factor Myc forms binary complexes with its binding partner Max. These and other bHLH-LZ-based protein-protein interactions (PPI) in the Myc-Max network are essential for the physiological and oncogenic activities of Myc. We have generated a genetically determined and highly specific protein-fragment complementation assay based on Renilla luciferase to analyze the dynamic interplay of bHLH-LZ transcription factors Myc, Max, and Mxd1 in vivo. We also applied this PPI reporter to quantify alterations of nuclear Myc-Max complexes in response to mutational events, competitive binding by the transcriptional repressor Mxd1, or perturbations by small-molecule Myc inhibitors, including recently identified potent PPI inhibitors from a Kröhnke pyridine library. We show that the specificity of Myc-Max PPI reduction by the pyridine inhibitors directly correlates with their efficient and highly specific potential to interfere with the proliferation of human and avian tumor cells displaying deregulated Myc expression. In a direct comparison with known Myc inhibitors using human and avian cell systems, the pyridine compounds reveal a unique inhibitory potential even at sub-micromolar concentrations combined with remarkable specificity for the inhibition of Myc-driven tumor cell proliferation. Furthermore, we show in direct comparisons using defined avian cell systems that different Max PPI profiles for the variant members of the Myc protein family (c-Myc, v-Myc, N-Myc, L-Myc) correlate with their diverse oncogenic potential and their variable sensitivity to the novel pyridine inhibitors.

Product Number
Product Description

10058-F4, ≥98% (HPLC), solid
10074-G5, ≥98% (HPLC)
Anti-Renilla Luciferase Antibody, clone 5B11.2, ascites fluid, clone 5B11.2, Chemicon®
Anti-Renilla Luciferase Antibody, clone 1D5.2, ascites fluid, clone 1D5.2, Chemicon®

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.